<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884089</url>
  </required_header>
  <id_info>
    <org_study_id>16536</org_study_id>
    <secondary_id>I3Y-MC-JPCK</secondary_id>
    <nct_id>NCT02884089</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants</brief_title>
  <official_title>Effect of Abemaciclib on Metformin Pharmacokinetics and Iohexol Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at how a single dose of abemaciclib will impact the body's ability to
      get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the
      effect of a single dose of abemaciclib on kidney function by measuring blood and urine
      markers. Side effects will also be documented.

      Each participant will complete four study periods. During each study period, participants
      will stay in the clinical research unit for nine days and eight nights.

      The study will last approximately 10 weeks, not including screening. Screening is required
      within 28 days prior to the start of the study.

      This study is for research purposes only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-∞]) of Metformin</measure>
    <time_frame>Predose through 6 days post dose in two of four study periods</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin</measure>
    <time_frame>Predose through 6 days post dose in two of four study periods</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin</measure>
    <time_frame>Predose through 6 days post dose in two of four study periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol</measure>
    <time_frame>Predose through 6 days post dose in two of four study periods</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo + Metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Iohexol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib + Iohexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Abemaciclib + Metformin</arm_group_label>
    <arm_group_label>Abemaciclib + Iohexol</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo + Metformin</arm_group_label>
    <arm_group_label>Abemaciclib + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Administered intravenously (IV)</description>
    <arm_group_label>Placebo + Iohexol</arm_group_label>
    <arm_group_label>Abemaciclib + Iohexol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo + Metformin</arm_group_label>
    <arm_group_label>Placebo + Iohexol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy surgically sterile or postmenopausal females and sterile males

          -  Have a body mass index (BMI) between 18 and 32 kilograms per meter squared (kg/m²),
             inclusive at screening

        Exclusion Criteria:

          -  Have known allergies to abemaciclib, metformin, iodine, iohexol, related compounds, or
             any components of the formulation

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence and/or positive antibodies of human immunodeficiency virus (HIV),
             hepatitis B, or hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dallas Clinical Research Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

